Home » Topics » BioWorld Science

BioWorld Science
RSS

Spartaject busulfan to enter phase I

April 5, 1996

ImmuCell arranges for clinical evaluation of CryptoGAM

April 5, 1996

DuPont Merck research into protease inhibitors

April 5, 1996

New data, new approvals for DaunoXome

April 5, 1996

Virend entering phase III

April 5, 1996

New protease inhibitors from BMS

April 5, 1996

Nabi foresees phase I/II trials on CMV NeutraGAM

April 5, 1996

Lidakol formulations receive patent protection

April 5, 1996

Pfizer, Microcide to codevelop antibacterial drugs

April 5, 1996

BILD-1351 for HSV infection

April 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 5, 2025.
CMS vows to put more emphasis on MA plans’ prior authorization
BioWorld MedTech
Physicians aren’t the only ones who see prior authorization (PA) practices as a significant problem, but John Brooks, deputy administrator at CMS, told a med tech...
100 days of uncertainty
BioWorld
The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
Associate degree: PTC’s hints of phase II HD efficacy studied
BioWorld
PTC Therapeutics Inc. CEO Matthew Klein said the firm “achieved all we set out to [achieve] in phase II” with PTC-518 in Huntington’s disease (HD), but it wasn’t...